Ardent: Solid Q1 Beat but Conservative 2026 Outlook Keeps Rating at Hold

Analyst Scott Fidel of Goldman Sachs maintained a Hold rating on Ardent Health Partners, Inc., with a price target of $12.00.

Scott Fidel has given his Hold rating due to a combination of factors that balance Ardent’s strong near‑term results with a more cautious longer‑term view. The company delivered a solid first‑quarter earnings beat on adjusted EBITDA, driven by better‑than‑expected revenue growth from pricing and admissions, along with improved labor and supply cost management.

At the same time, management merely reiterated its 2026 revenue and EBITDA outlook rather than raising it, signaling a reserved stance despite recent upside. In particular, Ardent is seeing better performance in its ACA exchange business but is still embedding conservative assumptions for that segment in its multi‑year guidance, which tempers the impact of the current beat and supports a neutral, Hold recommendation.

In another report released yesterday, Morgan Stanley also maintained a Hold rating on the stock with a $12.00 price target.